K Raghavendra Rao, chairman and managing director, Orchid Chemicals says the company has approached State Bank of India to delay the repayment of its USD 300 million debt.

Allecra deal to infuse USD 1m in cash: Orchid Chemicals

K Raghavendra Rao, chief managing director, Orchid Chemicals and Pharmaceuticals says the company will continue to supply Cephalosporin to regulated markets including US.

Hospira deal to be Rs 7-8 EPS accretive: Orchid Chemicals

Shares of Orchid Chemicals were on the rise after the pharmaceutical company sold its penicillin and penem business to US-based Hospira Inc for USD 200 million.

Orchid Chemicals sees 20% growth in FY12 vs 25% earlier

Orchid Chemicals and Pharmaceuticals expects its sales will grow at a slower 20% than the 25% it had seen earlier.

Orchid Chem to repay FCCB through ECB, borrows $100 mn

K Raghavendra Rao, chairman and managing director, Orchid Chemicals spoke to CNBC-TV18 about the fund-raising the company has undertaken and strategies of the company going ahead.

Operations not impacted by fire at Chennai lab: Orchid Chem

In an interview to CNBC-TV18, K Raghavendra Rao, managing director of Orchid Chemicals & Pharmaceuticals Ltd, said a fire took place last morning in one of the laboratories of basic research wing. However, he said, operations are not impacted by fire. “There is no impact on the commercial aspect of business.”

Orchid Chem in bad state, may fund debt with another one

Orchid Chemicals seems to be in a bad situation. K Raghavendra Rao, managing director, Orchid Chemicals & Pharmaceuticals is concerned that raising equity might be difficult at this point.

No impact on margin until share price halves: Orchid Chem

K Raghavendra Rao, MD of Orchid Chemicals & Pharmaceuticals, in an interview with CNBC-TV18’s Udayan Mukherjee and Mitali Mukherjee, said that unless their share price halves, there won't be any impact on the margins.